Nattawat Klomjit, MD, expresses enthusiasm for participating in the upcoming American Society of Nephrology Kidney Week 2024 in San Diego. Dr Klomjit highlights recent advancements in treating glomerular diseases, particularly IgA nephropathy, which now has three FDA-approved medications, a significant change from decades past.
He is also looking forward to hearing updates on therapeutic advances in the pipeline, including APRIL and BAFF inhibitors, CD38 blockades, and C5 inhibitors. In addition, in light of recent publications, he anticipates updates on the use of CAR T-cell therapy in autoimmune disease.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASN 2024: Previewing Developments in Glomerular Disease - Medscape - Oct 16, 2024.
Comments